TWI266800B - Polyol-IFN-beta conjugates - Google Patents

Polyol-IFN-beta conjugates

Info

Publication number
TWI266800B
TWI266800B TW093123043A TW93123043A TWI266800B TW I266800 B TWI266800 B TW I266800B TW 093123043 A TW093123043 A TW 093123043A TW 93123043 A TW93123043 A TW 93123043A TW I266800 B TWI266800 B TW I266800B
Authority
TW
Taiwan
Prior art keywords
ifn
beta
peg
polyol
conjugates
Prior art date
Application number
TW093123043A
Other languages
English (en)
Inventor
Tayer Nabil El
Michael J Roberts
Milton Harris
Wayne Sawlivich
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of TWI266800B publication Critical patent/TWI266800B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
TW093123043A 1998-04-28 1999-07-26 Polyol-IFN-beta conjugates TWI266800B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8333998P 1998-04-28 1998-04-28

Publications (1)

Publication Number Publication Date
TWI266800B true TWI266800B (en) 2006-11-21

Family

ID=22177687

Family Applications (2)

Application Number Title Priority Date Filing Date
TW088112596A TWI232882B (en) 1998-04-28 1999-07-26 Poly-IFN-beta conjugates
TW093123043A TWI266800B (en) 1998-04-28 1999-07-26 Polyol-IFN-beta conjugates

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW088112596A TWI232882B (en) 1998-04-28 1999-07-26 Poly-IFN-beta conjugates

Country Status (31)

Country Link
US (3) US6638500B1 (zh)
EP (2) EP1421956B1 (zh)
JP (2) JP4574007B2 (zh)
KR (1) KR100622796B1 (zh)
CN (2) CN1187094C (zh)
AR (1) AR020070A1 (zh)
AT (2) ATE365563T1 (zh)
AU (1) AU762621B2 (zh)
BG (2) BG64694B1 (zh)
BR (1) BR9910023A (zh)
CA (2) CA2330451A1 (zh)
CY (1) CY1108022T1 (zh)
CZ (2) CZ298579B6 (zh)
DE (2) DE69936409T2 (zh)
DK (2) DK1075281T3 (zh)
EA (2) EA003789B1 (zh)
EE (1) EE05214B1 (zh)
ES (2) ES2285286T3 (zh)
HK (2) HK1038194A1 (zh)
HU (1) HUP0300548A3 (zh)
IL (1) IL139286A (zh)
NO (2) NO329749B1 (zh)
NZ (1) NZ507456A (zh)
PL (2) PL196533B1 (zh)
PT (2) PT1075281E (zh)
SI (2) SI1075281T1 (zh)
SK (2) SK286217B6 (zh)
TR (2) TR200003161T2 (zh)
TW (2) TWI232882B (zh)
UA (2) UA79430C2 (zh)
WO (1) WO1999055377A2 (zh)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
DK1656952T3 (da) * 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
CA2343094A1 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
EP1579874A3 (en) * 1999-04-23 2006-01-25 ALZA Corporation Conjugate having a cleavable linkage for use in a liposome
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
TR200101086A3 (zh) * 1999-10-15 2001-08-21
ATE522563T1 (de) 1999-12-24 2011-09-15 Kyowa Hakko Kirin Co Ltd Verzweigte polyalkylenglykole
ES2327606T3 (es) 2000-01-10 2009-11-02 Maxygen Holdings Ltd Conjugados de g-csf.
PL204285B1 (pl) 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
WO2002060978A1 (fr) 2001-01-30 2002-08-08 Kyowa Hakko Kogyo Co., Ltd. Polyalkylene glycols ramifies
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
CA2469846A1 (en) 2001-02-27 2002-09-26 Maxygen Aps New interferon beta-like molecules
ATE468862T1 (de) 2001-07-11 2010-06-15 Maxygen Inc G-csf konjugate
BRPI0306993B8 (pt) 2002-01-18 2021-05-25 Biogen Idec Inc polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EA008866B1 (ru) 2002-12-26 2007-08-31 Маунтин Вью Фамэсьютикэлс, Инк. ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
PL396711A1 (pl) 2002-12-26 2011-12-19 Mountain View Pharmaceuticals, Inc. Koniugaty polimerów z cytokinami, chemokinami, czynnikami wzrostu, hormonami polipeptydowymi i ich antagonistami, kompozycja farmaceutyczna i sposób zapobiegania, diagnozowania lub leczenia
CA2519873C (en) 2003-03-20 2012-12-18 Maxygen Holdings Ltd. Fvii or fviia variants
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
JP4896745B2 (ja) * 2004-02-02 2012-03-14 アンブレツクス・インコーポレイテツド 修飾されたヒトインターフェロンポリペプチドおよびこれらの使用
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
WO2006069220A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. Modified human growth hormone
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
NZ550926A (en) 2004-05-17 2010-01-29 Ares Trading Sa Hydrogel interferon formulations
BRPI0510527A (pt) 2004-06-01 2007-10-30 Ares Trading Sa método de estabilização de proteìnas
BRPI0510526A (pt) 2004-06-01 2007-10-30 Ares Trading Sa formulações lìquidas estabilizadas de interferon
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
ATE494012T1 (de) 2004-12-21 2011-01-15 Nektar Therapeutics Stabilisierte polymer-thiol-reagenzien
MX2007007587A (es) 2004-12-22 2007-12-11 Ambrx Inc Formulaciones de la hormona del crecimiento humano que comprenden un aminoacido codificado de manera no natural.
KR20070100299A (ko) 2004-12-22 2007-10-10 암브룩스, 인코포레이티드 재조합 인간 성장 호르몬의 발현 및 정제 방법
US8633300B2 (en) 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
JP2009503111A (ja) * 2005-08-04 2009-01-29 ネクター セラピューティックス エイエル，コーポレイション Ｇ−ｃｓｆ部分および重合体の複合体
RS57549B1 (sr) 2005-08-26 2018-10-31 Ares Trading Sa Proces za pripremu glikoziliranog interferona beta
KR20080050591A (ko) 2005-09-01 2008-06-09 아레스 트레이딩 에스.에이. 시신경염 치료
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
AU2007248680C1 (en) * 2006-05-02 2014-01-23 Allozyne, Inc. Non-natural amino acid substituted polypeptides
RU2008145084A (ru) 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
JP2009537605A (ja) 2006-05-24 2009-10-29 メルク セローノ ソシエテ アノニム 多発性硬化症を治療するためのクラドリビン・レジメン
NZ580686A (en) 2007-05-02 2012-11-30 Ambrx Inc Modified interferon beta polypeptides and their uses
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
ATE555812T1 (de) * 2007-12-20 2012-05-15 Merck Serono Sa Peg-interferon-beta-formulierungen
CN101939443B (zh) 2008-02-08 2014-01-29 Ambrx公司 经修饰瘦素多肽和其用途
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
US20100112660A1 (en) * 2008-05-30 2010-05-06 Barofold, Inc. Method for Derivatization of Proteins Using Hydrostatic Pressure
US20110124614A1 (en) * 2008-10-25 2011-05-26 Halina Offner Methods And Compositions For The Treatment of Autoimmune Disorders
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
CN102770449B (zh) 2010-02-16 2016-02-24 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
US20120135912A1 (en) 2010-05-10 2012-05-31 Perseid Therapeutics Llc Polypeptide inhibitors of vla4
WO2012007324A2 (en) 2010-07-15 2012-01-19 Novo Nordisk A/S Stabilized factor viii variants
JP6042335B2 (ja) 2010-09-15 2016-12-14 ノヴォ ノルディスク アー／エス 細胞取込みが低下した第ｖｉｉｉ因子変異体
JP2014506889A (ja) * 2011-02-18 2014-03-20 ステムディーアール インク． Ｓｉｒｔ１発現誘導物質を含む敗血症または敗血症性ショックの予防または治療用組成物
KR20140054009A (ko) 2011-07-01 2014-05-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신 융합 폴리펩타이드 및 그의 용도
SG11201401071YA (en) * 2011-10-01 2014-08-28 Glytech Inc Glycosylated polypeptide and pharmaceutical composition containing same
CA3179537A1 (en) 2012-02-27 2013-09-06 Amunix Pharmaceuticals, Inc. Xten conjugate compositions and methods of making same
KR20140130705A (ko) 2012-02-29 2014-11-11 도레이 카부시키가이샤 체강액 저류 억제제
MY171183A (en) 2013-03-29 2019-09-30 Glytech Inc Polypeptide glycosylated with sialylated sugar chain
WO2016013911A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 페길화된 인터페론 -베타 변이체
WO2016013697A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체
LT3183264T (lt) 2014-08-19 2021-01-11 Biogen Ma Inc. Pegilinimo būdas
US10987401B2 (en) 2015-05-01 2021-04-27 Allysta Pharmaceuticals, Inc. Adiponectin peptidomimetics for treating ocular disorders
EP3310816B1 (en) * 2015-06-19 2020-09-09 Eisai R&D Management Co., Ltd. Cys80 conjugated immunoglobulins
CA3059592A1 (en) * 2017-04-17 2018-10-25 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
CN113382775A (zh) 2019-01-28 2021-09-10 东丽株式会社 肝细胞生长因子或其活性片段的聚乙二醇修饰物
US20220220176A1 (en) 2019-01-28 2022-07-14 Toray Industries, Inc. Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
JP2524586B2 (ja) * 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5208344A (en) * 1987-07-31 1993-05-04 American Home Products Corporation Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
WO1995013090A1 (en) 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
JP2996415B2 (ja) 1994-03-31 1999-12-27 アムジエン・インコーポレーテツド 巨核球の成長と分化を刺激するモノｐｅｇ化ｍｇｄｆポリペプチド
DE69534318T2 (de) * 1994-05-18 2006-04-20 Nektar Therapeutics, San Carlos Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
KR0176625B1 (ko) 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
DE69800640T2 (de) * 1997-01-29 2001-07-05 Polymasc Pharmaceuticals Plc L Pegylationsverfahren
AU751898B2 (en) * 1997-07-14 2002-08-29 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates

Also Published As

Publication number Publication date
CA2330451A1 (en) 1999-11-04
AU3767499A (en) 1999-11-16
UA66857C2 (uk) 2004-06-15
TR200101751T2 (tr) 2002-05-21
CZ298597B6 (cs) 2007-11-21
KR100622796B1 (ko) 2006-09-13
CA2565375A1 (en) 1999-11-04
TR200003161T2 (tr) 2001-01-22
HUP0300548A3 (en) 2005-07-28
WO1999055377A9 (en) 2000-03-02
NO20100324L (no) 2000-12-28
US6638500B1 (en) 2003-10-28
CN1637020A (zh) 2005-07-13
UA79430C2 (en) 2007-06-25
US20040043002A1 (en) 2004-03-04
BG104871A (en) 2001-07-31
DE69920002T2 (de) 2005-09-22
SK286217B6 (sk) 2008-05-06
ES2285286T3 (es) 2007-11-16
NO329749B1 (no) 2010-12-13
HUP0300548A2 (hu) 2003-06-28
ES2224649T3 (es) 2005-03-01
EE200000614A (et) 2002-04-15
EP1421956A1 (en) 2004-05-26
CN1302209A (zh) 2001-07-04
CN100335503C (zh) 2007-09-05
BG65046B1 (bg) 2007-01-31
EP1421956B1 (en) 2007-06-27
NO20005337L (no) 2000-12-28
EE05214B1 (et) 2009-10-15
EP1075281B1 (en) 2004-09-08
BG64694B1 (bg) 2005-12-30
CY1108022T1 (el) 2013-09-04
AR020070A1 (es) 2002-04-10
EA200300382A1 (ru) 2005-02-24
US20070141620A1 (en) 2007-06-21
BG109291A (en) 2006-04-28
CN1187094C (zh) 2005-02-02
AU762621B2 (en) 2003-07-03
IL139286A (en) 2005-12-18
PL344490A1 (en) 2001-11-05
NO20005337D0 (no) 2000-10-23
NZ507456A (en) 2003-10-31
DE69936409T2 (de) 2008-04-17
CZ20003995A3 (en) 2001-06-13
EA005495B1 (ru) 2005-02-24
KR20010071158A (ko) 2001-07-28
DE69936409D1 (de) 2007-08-09
DK1421956T3 (da) 2007-10-01
PL193352B1 (pl) 2007-02-28
PT1075281E (pt) 2004-11-30
SK16222000A3 (sk) 2001-04-09
PT1421956E (pt) 2007-07-13
DK1075281T3 (da) 2005-01-03
WO1999055377A2 (en) 1999-11-04
JP4574007B2 (ja) 2010-11-04
SI1075281T1 (en) 2005-02-28
JP2002512983A (ja) 2002-05-08
ATE365563T1 (de) 2007-07-15
US7357925B2 (en) 2008-04-15
US7700314B2 (en) 2010-04-20
EA003789B1 (ru) 2003-10-30
BR9910023A (pt) 2000-12-26
EP1075281A2 (en) 2001-02-14
DE69920002D1 (de) 2004-10-14
WO1999055377A3 (en) 1999-12-29
SI1421956T1 (sl) 2007-10-31
IL139286A0 (en) 2001-11-25
NO332224B1 (no) 2012-07-30
HK1076115A1 (en) 2006-01-06
PL196533B1 (pl) 2008-01-31
SK286654B6 (sk) 2009-03-05
TWI232882B (en) 2005-05-21
JP2010184929A (ja) 2010-08-26
EA200001111A1 (ru) 2001-04-23
HK1038194A1 (en) 2002-03-08
ATE275422T1 (de) 2004-09-15
CZ298579B6 (cs) 2007-11-14

Similar Documents

Publication Publication Date Title
TWI266800B (en) Polyol-IFN-beta conjugates
WO2006004959A3 (en) Pegylated interferon alpha-1b
CA2158054A1 (en) Conjugates of proteins and bifunctional ligands
DE69925830D1 (de) Peg-lhrh analog konjugate
DE69835201D1 (en) Neoglycoproteine
CA2312004A1 (en) Site-specific preparation of polyethylene glycol-grf conjugates
WO2003022210A3 (en) Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
MX9700552A (es) Conjugados de vitamina b12 y proteinas.
UA103758C2 (ru) Конъюгаты олигомеров инсулина, их композиции и применение
ZA902949B (en) A novel antibody delivery system for biological response modifiers
CA2345027A1 (en) Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
EP1698629A3 (en) Polyamines and their use in therapy
HU911929D0 (en) Process for the production of conjugates containing orto ligating functional group from chelate complexes and joint antibodies or antibody fragments and the medical preparations containing thereof
WO1999065506A3 (en) Cancer therapy with indolicidin or cationic peptides and their polymer conjugates
TR199902775T2 (xx) 20(S)-Kamptotesin glikokonjugeleri.
TWI266801B (en) Polyol-IFN-beta conjugates